Find Funding
Below are funding resources from the National Institutes of Health (NIH), the UCLA Health Jonsson Comprehensive Cancer Center and UCLA. For more information on UCLA Health JCCC-related funding opportunities, please visit our Internal Funding and External Funding pages.
NIH Funding Resources
NIH Grants and Funding Search Guide
UCLA Health Jonsson Comprehensive Cancer Center Funding Resources
Extramural Quarterly Funding Announcement
The UCLA Health JCCC provides an Extramural Quarterly Funding Announcement for UCLA investigators. This includes currently open extramural funding opportunities that are of interest to UCLA investigators. it is emailed directly to members.
Extramural Limited Submission Funding Opportunities
Limited extramural funding opportunities are provided below as a courtesy to UCLA Health JCCC members. For an opportunity to be included on this list, it must be a cancer-relevant Limited Submission Opportunity (LSO). LSOs for NIH Administrative Supplements responsive to the UCLA Health JCCC’s Support Grant, P30CA016042, are also included on this list. Submission instructions are noted below.
For more information, please visit our online funding portal, InfoReady. Here, you can find detailed information about available LSOs and explore the home page for more opportunities. If you have any questions about specific LSOs listed below or about NIH Administrative Supplements (under UCLA Health JCCC’s Support Grant, P30CA016042), please contact Sarah Anwar Tar via email.
Administrative Supplement to P30 Cancer Center Support Grants (CCSG), P50 Specialized Programs of Research Excellence (SPORE) Grants, and U54 Specialized Patient-Derived Xenograft Network (PDXNet) Grants to Develop Autologous Human Immune Mouse Models and Organoid Systems for Cancer Immunotherapy Evaluations
Patient-derived xenografts (PDX) have the potential to improve preclinical evaluation of novel anticancer therapies. NCI maintains programmatic interest in understanding the reproducibility and translatability of PDX drug response experiments using PDX models and organoid systems for testing therapies and in making such models available to the wider community. To further this pursuit, NCI is specifically seeking research proposals that recreate human immune responses using pluripotent stem cells and human primary tissue and the like, for immunotherapies alone or combined with cancer treatments.
Preclinical models in which both the immunity and the tumor are of human origin and genetically identical are critical to advancing immunotherapies alone or in combination with other modalities. Research is now underway to recreate human immune responses using novel PDX-based strategies, patient derived organoids, and human induced pluripotent stem cell (iPSC). Research has also shown that iPSCs can be generated by reprogramming adult cells (skin fibroblast and blood cells) back into a pluripotent state through the introduction of Oct4, Sox2, Klf4, and c-Myc genes referred to as the Yamanaka factor. By reprogramming cells from cancer patients, iPSCs that carry the same cancer-associated genetic mutations found in the patient’s tumor cells can be generated. The combination of these platforms can create a portfolio of advanced humanized mice-tumor models appropriate for studying molecular mechanisms underlying tumorigenesis and exploring novel immunotherapeutic strategies more fully.
How to apply
To submit your nomination application, please access our 2025 NCI Adminstrative Supplements grants online application via InfoReady.
Deadline
Please submit a one-page research summary and a current NIH Biosketch by Tuesday, July 22, 2025 at 5pm PST.
UCLA Funding Resources
We Want to Hear from You!
Help us improve your experience with our services! Click the Take Survey button to take a short three-question survey.